Table 2.
Comprehensive HLA haplotype analysis of HLA-A, -C and -B in Japanese severe COVID-19 and Japanese healthy control.
Locus | Allele | Control (2n=846) % | Severe_COVID (2n=106)% | OR (95% CI) | p.value | p.corrected |
---|---|---|---|---|---|---|
A~C~B | 24:02:01:01~07:02:01:03~07:02:01:01 | 5.8 | 0.9 | 0.16 (0.00-0.93) | 0.035 | NS |
A~C~B | 24:02:01:01~12:02:02:01~52:01:01:02 | 8.9 | 17.0 | 2.09 (1.12-3.72) | 0.008 | 0.033 |
A~C~B | 33:03:01:01~14:03:01:01~44:03:01:10 | 7.6 | 6.6 | 0.85 (0.32-1.93) | 0.703 | NS |
A~C~B | binned | 77.7 | 75.5 | 0.89 (0.54-1.48) | 0.611 | NS |
C~B | 01:02:01:05~54:01:01:01 | 7.9 | 6.6 | 0.83 (0.31-1.87) | 0.645 | NS |
C~B | 03:03:01:01~35:01:01:02 | 5.9 | 4.7 | 0.79 (0.24-2.03) | 0.621 | NS |
C~B | 03:04:01:02~40:02:01:01 | 5.2 | 3.8 | 0.71 (0.18-2.02) | 0.524 | NS |
C~B | 07:02:01:03~07:02:01:01 | 6.8 | 3.8 | 0.54 (0.14-1.49) | 0.228 | NS |
C~B | 12:02:02:01~52:01:01:02 | 9.4 | 18.9 | 2.25 (1.24-3.92) | 0.003 | 0.020 |
C~B | 14:02:01:01~51:01:01:01 | 5.8 | 5.7 | 0.98 (0.33-2.36) | 0.958 | NS |
C~B | 14:03:01:01~44:03:01:10 | 8.2 | 6.6 | 0.79 (0.30-1.78) | 0.564 | NS |
C~B | binned | 50.8 | 50.0 | 0.97 (0.63-1.48) | 0.875 | NS |
A~C | 24:02:01:01~07:02:01:03 | 5.8 | 0.9 | 0.16 (0.00-0.93) | 0.035 | NS |
A~C | 24:02:01:01~12:02:02:01 | 9.0 | 17.0 | 2.06 (1.11-3.67) | 0.010 | 0.039 |
A~C | 33:03:01:01~14:03:01:01 | 7.8 | 6.6 | 0.84 (0.32-1.90) | 0.674 | NS |
A~C | binned | 77.4 | 75.5 | 0.90 (0.55-1.50) | 0.650 | NS |
A~B | 24:02:01:01~07:02:01:01 | 5.9 | 0.9 | 0.15 (0.00-0.91) | 0.032 | NS |
A~B | 24:02:01:01~52:01:01:02 | 9.0 | 17.0 | 2.06 (1.11-3.67) | 0.010 | 0.039 |
A~B | 33:03:01:01~44:03:01:10 | 7.6 | 6.6 | 0.85 (0.32-1.93) | 0.703 | NS |
A~B | binned | 77.4 | 75.5 | 0.90 (0.55-1.50) | 0.650 | NS |
Significant HLA haplotypes after multiple correction are highlighted in bold.
OR, odd ratio; 95% CI, 95% confidence interval; Pc-value, multiple testing corrected p-value; binned, rare HLA alleles with expected count < 5 are combined into a common class